Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials

Dean Follmann(National Institute of Allergy and Infectious Diseases), Kathleen M. Neuzil(Center for Global Development), Michal Juraska(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Yunda Huang(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), David Benkeser(Emory University), Devan V. Mehrotra(United States Military Academy), Alex Luedtke(University of Washington), Ying Huang(Fred Hutch Cancer Center), Michael P. Fay(National Institutes of Health), Iksung Cho(Yonsei University), Myron S. Cohen(University of North Carolina at Chapel Hill), Hana M. El Sahly(Baylor College of Medicine), James G. Kublin(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Jonathan Fintzi(National Institutes of Health), Holly Janes(Fred Hutch Cancer Center), Martha Nason(National Institutes of Health), An Vandebosch(University of Maryland, Baltimore), Lawrence Corey(Fred Hutch Cancer Center), Deborah Donnell(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Youyi Fong(Fred Hutch Cancer Center), Peter B. Gilbert(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Lindsay N. Carpp(Fred Hutch Cancer Center), Marco Carone(University of California, Berkeley), Ollivier Hyrien(Fred Hutch Cancer Center), Thomas R. Fleming(University of Washington), Lindsey R. Baden(Brigham and Women's Hospital), Erin E. Gabriel(Karolinska Institutet), Shu Han(Sichuan University), Ian Hirsch(AstraZeneca (United Kingdom))
medRxiv
December 14, 2020
Cited by 25


Related Papers